Charité - Universitätsmedizin Berlin
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1710-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.charite.de
Clinical Trials
1.1k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (694 trials with phase data)• Click on a phase to view related trials
Post-intensive Care Syndromes in Pregnant Patients With Respiratory Failure and COVID-19 Compared to Non-pregnant Patients With Respiratory Failure and COVID-19
- Conditions
- COVID-19Acute Respiratory Distress Syndrome Due to COVID-19Pregnancy Related
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 40
- Registration Number
- NCT07051967
- Locations
- 🇩🇪
Department of Anesthesiology and Intensive Care Medicine (CCM/CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany
Feasibility of Empowerment Group Therapy on Ukrainian Adult Outpatients
- Conditions
- Depression NOS
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 55
- Registration Number
- NCT07048990
- Locations
- 🇺🇦
National Medical University Bogomolets, Kyiv, Ukraine
Effects of the Clinical Application of Traditional, Complementary and Integrative Medicine (TCIM) Procedures During Inpatient Stays in Germany
- Conditions
- Chronic Disease
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 2500
- Registration Number
- NCT07040475
- Locations
- 🇩🇪
Sozialstiftung Bamberg, Klinikum Bamberg, Bamberg, Germany
🇩🇪Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus, Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Charité - Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Klinik für Naturheilkunde und Integrative Medizin, KEM, Essen, Germany
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Drug: FOLFIRI+cetuximabDiagnostic Test: Guardant360 ctDNA assay
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 267
- Registration Number
- NCT07004413
- Locations
- 🇩🇪
Charite University, Berlin, Berlin, Germany
VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle
- Conditions
- VaccinationMetabolismImmunosenescence
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 24
- Registration Number
- NCT07000708
- Locations
- 🇩🇪
Clinical Research Unit, Experimental & Clinical Research Center, Campus Buch, Charité, Berlin, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 164
- Next
News
Simvastatin Fails to Show Antidepressant Benefits in Major Depression and Obesity Trial
A randomized controlled trial of 161 patients with major depressive disorder and obesity found that adding simvastatin to escitalopram provided no additional antidepressant benefits compared to placebo.
Alys Pharmaceuticals Advances First-in-Class Mast Cell-Selective c-Kit Inhibitor ALY-301 to Clinical Trials for Cold Urticaria
Alys Pharmaceuticals has submitted a Clinical Trial Application to Germany's Paul-Ehrlich-Institut for ALY-301, a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity.
PEARLDIVER: Europe-Wide Platform Trial Aims to Accelerate Depression Treatment Development
The PEARLDIVER project, a Europe-wide platform study, will evaluate multiple depression treatments simultaneously using a shared infrastructure.